Skip to content
Screener

Immix Biopharma, Inc. IMMX Q4 2024 Annual earnings

Reported March 24, 2025 · Before market open

Revenue$96.3K
EPS-$0.16Beat by $0.09
EPS estimate-$0.25

Next report

Nov 6, 2026 (in 2 months)
EPS estimate-$0.18

Financials

Q4 2024

Income statement

See full
Operating income-$5.0M+7.2%
Net income-$4.8M+5.5%
EPS (diluted)-$0.16+33.3%

Balance sheet

See full
Cash & equivalents$17.7M+1.0%
Total debt$1.1M—
Total equity$13.3M-19.2%
Total assets$22.9M+15.2%

Cash flow

See full
Operating cash flow-$1.5M+44.9%
CapEx$507.2K+3,749%
Free cash flow-$2.0M+26.3%

Valuation & ratios

Valuation

as of 12/31/24
See full
Market cap$60.52M-56.1%
Enterprise value$43.91M—

Returns & leverage

See full
Return on equity-145.8%+95.9pp
Debt / equity0.1×—
Current ratio2.3×-3.0×

FAQ

When did Immix Biopharma, Inc. report Q4 2024 earnings?
Immix Biopharma, Inc. (IMMX) reported Q4 2024 earnings on March 24, 2025 before market open.
What were Immix Biopharma, Inc.'s Q4 2024 revenue and EPS?
Immix Biopharma, Inc. reported revenue of $96.3K and eps of $-0.16 for Q4 2024.
Did Immix Biopharma, Inc. beat estimates in Q4 2024?
EPS beat the consensus estimate of $-0.25 by $0.09.
Where can I find Immix Biopharma, Inc.'s Q4 2024 SEC filings?
You can read the 10-K periodic report (0001641172-25-000387) directly on SEC EDGAR. The filing index links above go to sec.gov.